Lexicon pharmaceuticals, inc./de (LXRX)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Revenues:
Net product revenue

0

-

0

0

0

-

24,509

24,053

20,629

-

10,443

4,613

721

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaborative agreements

29,900

32,331

289,000

3,646

9,190

26,583

-4,099

16,457

18,157

15,890

-13,400

-6,826

5,071

0

60,686

33,338

0

-

0

0

-

22,593

2,487

2,413

1,997

2,109

951

927

915

783

885

1,006

1,268

1,632

1,944

2,773

0

0

0

Royalties and other revenue

588

511

445

382

310

355

398

274

253

178

100

131

162

155

180

187

0

-

0

0

-

261

295

188

142

113

79

237

234

306

329

191

285

217

343

392

0

0

0

Total revenues

320,856

322,073

330,417

42,935

47,051

63,209

80,539

100,515

98,770

91,689

76,244

77,019

85,055

79,256

187,580

160,429

140,716

130,014

24,216

24,069

24,369

22,854

2,782

2,601

2,139

2,222

1,030

1,164

1,149

1,089

1,214

1,197

1,553

1,849

2,287

3,165

0

0

0

Operating expenses:
Cost of sales (including finite-lived intangible asset amortization)

3,246

3,231

3,026

3,000

2,511

2,491

2,460

2,508

2,207

1,899

1,361

762

225

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development, including stock-based compensation of $2,176 and $1,768, respectively

135,083

91,924

63,625

50,729

64,569

100,243

130,507

155,881

156,338

152,223

135,874

149,270

170,552

163,973

168,193

138,771

111,324

95,187

84,776

85,773

86,191

89,279

89,511

90,803

93,308

89,682

90,409

84,201

79,864

82,574

89,691

90,154

90,944

91,828

82,662

83,246

0

0

0

Earnings Per Share, Diluted

-

-

1.95

-

-

-

-0.26

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Selling, general and administrative expenses, included stock-based compensation of $2,256 and $1,643, respectively

57,413

56,835

58,834

60,515

63,007

63,754

63,211

64,356

66,076

66,090

64,150

59,689

49,630

43,157

35,525

28,641

26,532

23,835

21,375

20,613

19,458

19,411

18,835

18,934

18,451

17,121

17,629

17,309

16,802

17,043

17,133

16,792

17,162

17,350

18,288

19,301

0

0

0

Increase in fair value of Symphony Icon, Inc. purchase liability

-

-

-

-

-

-

-

-

-

2,101

2,101

-45

433

-703

79

5,629

5,139

5,927

6,055

1,579

2,039

1,428

-4,771

-2,361

-2,332

-2,210

2,879

7,385

9,070

9,887

11,655

8,147

7,789

6,766

6,343

4,007

0

0

0

Impairment loss on buildings

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

224,380

180,628

154,123

114,244

130,087

166,488

196,178

222,745

224,621

222,313

203,486

209,676

220,840

206,427

205,045

176,638

146,592

128,546

114,555

121,067

120,790

123,220

116,677

107,376

109,427

104,593

110,917

108,895

105,736

109,504

118,479

115,093

115,895

115,944

107,293

106,554

0

0

0

Loss from operations

96,476

141,445

176,294

-71,309

-83,036

-103,279

-115,639

-122,230

-125,851

-130,624

-127,242

-132,657

-135,785

-127,171

-17,465

-16,209

-5,876

1,468

-90,339

-96,998

-96,421

-100,366

-113,895

-104,775

-107,288

-102,371

-109,887

-107,731

-104,587

-108,415

-117,265

-113,896

-114,342

-114,095

-105,006

-103,389

0

0

0

Gain on investments, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Interest income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

191

196

210

213

198

214

224

255

266

406

0

0

0

Interest expense

20,690

20,676

20,710

20,758

20,781

20,777

17,715

14,082

10,509

6,984

6,455

6,482

6,506

6,567

6,611

6,652

6,669

6,722

5,936

4,698

3,498

2,253

1,838

1,881

1,922

1,971

2,014

2,049

2,083

2,114

2,145

2,178

2,458

2,528

2,614

2,783

0

0

0

Interest and other income, net

3,519

3,350

2,890

3,073

3,292

3,508

3,259

2,891

2,429

1,954

1,938

2,087

2,186

2,293

1,816

1,334

1,056

572

1,840

2,045

2,314

2,255

1,094

818

276

216

125

118

143

105

29

113

122

153

-2,555

-3,286

0

0

0

Net income (loss) before taxes

-

-

0

-

-

-

0

-

-

-135,654

-131,759

-137,052

-140,105

-131,445

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

Income tax benefit

-

-

0

-

-

-

0

-

-

-12,700

-8,652

-8,652

-8,652

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Income tax benefit

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

Net loss

85,319

130,133

164,488

-88,994

-100,525

-120,548

-126,086

-129,412

-129,922

-122,993

-123,107

-128,400

-131,453

-131,445

-22,260

-21,527

-11,489

-4,682

-94,365

-99,581

-97,535

-100,294

-114,775

-105,935

-108,987

-104,126

-111,585

-109,466

-106,317

-110,211

-119,183

-115,747

-116,454

-116,215

-109,883

-108,973

0

0

0

Net loss per common share, Basic and Diluted

-0.63

-

2.13

-

-0.21

-

-0.26

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Shares used in computing net loss per common share, Basic and Diluted

106,536

-

106,272

-

106,054

-

105,881

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss per common share, basic and diluted

-

-

-

-0.22

-

-

-

-0.33

-0.40

-

-0.29

-0.33

-0.33

-0.21

-0.35

-0.37

-0.34

0.83

-0.34

-0.27

-0.27

-0.35

-0.55

-0.35

-0.06

-1.25

-0.06

-0.06

-0.05

-0.06

-0.06

-0.05

-0.06

-0.09

-0.08

-0.08

-0.09

-0.08

-0.07

Other comprehensive loss:
Unrealized gain on investments

827

96

107

304

427

210

-8

-4

-130

-27

-141

-550

-561

24

20

238

274

-156

56

93

13

-65

-36

-26

-32

-21

17

51

99

2

-13

-91

-97

16

0

0

0

-

-

Comprehensive loss

86,146

130,229

164,595

-88,690

-100,098

-120,338

-126,094

-129,416

-130,052

-123,020

-123,248

-128,950

-132,014

-131,421

-22,240

-21,289

-11,215

-4,838

-94,309

-99,488

-97,522

-100,359

-114,811

-105,961

-109,019

-104,147

-111,568

-109,415

-106,218

-110,209

-119,196

-115,838

-116,551

-116,199

0

0

0

-

-

Stock-based compensation expense associated with research and development expense

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation expense associated with selling, general and administrative expense

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted Average Number of Shares Outstanding, Diluted

-

-

116,640

106,272

-

105,923

105,881

105,848

105,668

105,605

105,582

105,300

104,461

104,055

103,885

103,830

103,682

103,624

103,616

103,608

103,516

-355,627

73,542

73,518

513,955

-1,245,722

513,419

513,083

512,428

507,821

490,049

480,634

480,324

350,171

337,678

337,668

337,527

337,404

337,404